ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0405

Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study

Ko Fujii, Motoki Horii, Natsumi Fushida, Tomoyuki Ikeda, Yasuhito Hamaguchi and Takashi Matsushita, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa Ishikawa, Japan

Meeting: ACR Convergence 2023

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-Th/To antibodies (Abs) have been reported in patients with systemic sclerosis (SSc). The presence of anti-Th/To Abs is detected in 2-5% of SSc cases and is more frequently observed in the limited cutaneous SSc (lcSSc). In the Japanese population, there is a higher incidence of concurrent gastroesophageal reflux disease (GERD) and interstitial lung disease (ILD), although the severity of these complications tends to be milder compared to European and North American populations. Due to the low expression frequency and few case reports on this Abs, there is no consensus on clinical significance of this Abs.

Methods: Thus, to examine the clinical characteristics of patients with anti-Th/To Abs, we retrospectively identified 10 patients by using the serum immunoprecipitation assays between 2001 and 2021.

Results: Among the anti-Th/To positive cases, only lcSSc was observed, and diffuse cutaneous SSc (dcSSc) was not detected.

Compared to 596 cases of Th/To-negative SSc from our hospital, the modified Rodnan total skin thickness score (mRSS) was significantly lower in the anti-Th/To positive group (2.8 [0-9] vs. 10.1 [0-49], p < 0.05). Additionally, there was a significantly higher rate of ILD (8/9 vs. 143/596, p < 0.01) and Pulmonary arterial hypertension (PAH) (3/9 vs. 41/596, p < 0.05) in the anti-Th/To-positive group compared to the negative group. Although there was no significant difference, GERD was more common in the anti-Th/To positive group (63%) compared to the negative group (44.3%). No cases of renal crisis were observed in patients with anti-Th/To positive SSc.

When compared to 170 SSc patients with anti-topoisomerase antibodies, which are known to be frequently associated with ILD, there was no significant difference. However, the anti-Th/To-positive group had a higher rate of ILD.

Conclusion: In conclusion, patients with anti-Th/To antibodies exhibit mild skin sclerosis but have an increased risk of developing organ complications such as ILD and PAH in the future.


Disclosures: K. Fujii: None; M. Horii: None; N. Fushida: None; T. Ikeda: None; Y. Hamaguchi: None; T. Matsushita: None.

To cite this abstract in AMA style:

Fujii K, Horii M, Fushida N, Ikeda T, Hamaguchi Y, Matsushita T. Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-features-of-anti-th-to-antibodies-positive-systemic-sclerosis-patients-a-single-center-retrospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-of-anti-th-to-antibodies-positive-systemic-sclerosis-patients-a-single-center-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology